Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_92977

Stem cell setback: Reprogrammed stem cells may induce immune response

23 May 2011
Appeared in BioNews 608

IPS cells from mice can be recognised by their own immune system and destroyed, even if they are genetically identical to the recipient of the cells, scientists at the University of California, San Diego, have found. Scientists had believed iPS cells wouldn't be identified as foreign and destroyed by the body, as happens with transplants using cells or organs from a different donor.

In this new study, led by Professor Yang Xu, researchers created iPS cells from mouse skin cells and transplanted them into genetically identical mice, a process similar to performing a transplant between identical twins.

The cells were attacked by the immune systems of the recipient mice and destroyed. This was in contrast to transplants using genetically identical embryonic stem cells (ES cells), which were not destroyed by the recipients' immune systems.

Professor Nissim Benvenisty, a stem-cell biologist at the Hebrew University of Jerusalem told Nature: 'We expected that iPS cells generated from patients would be able to be transplanted back into patients. This paper indicates that that may not be the case'.

But these findings do not mean that iPS cells could never be used in medicine. Professor Xu's team found using different methods to generate iPS cells altered the strength of the immune reaction against them. This appeared to be due to different levels of, gene expression by the  iPS cells.

Professor Xu told Nature: 'We propose that the technology to generate iPS cells needs to be improved in order to minimize the difference between iPS cells and ES cells, so that iPS cells can be more useful in human therapies'.

An editorial in the New Scientist called for the news to serve as a message to 'keep stem cell options open'. The study authors argue that the new findings demonstrate research on ES cells is still necessary, despite their ethically-sensitive nature, because they cannot yet be replaced entirely by research on iPS cells.

 

SOURCES & REFERENCES
Immunogenicity of induced pluripotent stem cells
Nature |  13 May 2011
Keep stem cell options open
New Scientist |  18 May 2011
Reprogrammed cells trigger immune reactions in mice
Nature |  13 May 2011
Stem cell setback as mice reject own tissue
New Scientist |  18 May 2011
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
12 September 2011 - by Daniel Malynn 
Presenter Liz Bonnin investigates stem cells, and their pioneering use in organ donation. Bonnin's introduction the segment covers briefly, but accurately, the 30 years worth of history of stem cell research, and the controversy around embryonic stem cell research...
11 July 2011 - by Dr Rebecca Robey 
Surgeons have successfully transplanted a synthetic organ into a human for the first time. In a groundbreaking operation, a cancer patient's windpipe was replaced with an artificial replica that had been grown using his own stem cells....
7 February 2011 - by Leo Perfect 
Adult human cells maintain a 'memory' when reprogrammed into a stem cell-like state, US scientists have found. The finding suggests the resulting induced pluripotent stem (iPS) cells are not yet a viable alternative to human embryonic stem (ES) cells for modelling or treating disease...
17 January 2011 - by Julianna Photopoulos 
An international team of researchers have found that both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) show higher genetic abnormalities than other cells....
2 August 2010 - by Dr Rachael Panizzo 
Stem cells created from a patients' own tissue are subtly different from those derived from embryos in ways that may affect their therapeutic potential, two independent research groups have found. Both studies found induced pluripotent stem cells (iPS) retain an 'epigenetic memory' of their tissue of origin...
22 February 2010 - by Dr Sophie Pryor 
A new study has cast doubt over how useful human induced pluripotent stem (iPS) cells could be for research and the treatment of degenerative disease...
15 February 2010 - by Nisha Satkunarajah 
A Californian biotechnology company has obtained the first US patent for developing a method to create stem cells from adult cells....
21 December 2009 - by Dr Will Fletcher 
A commercial product claiming to be the first to make use of induced pluripotent stem cells (iPS cells) has been launched, albeit not a product that can be directly used on humans. Cellular Dynamics International (CDI), a biotech company based in Madison, Wisconsin, US, has recently announced that it has released human heart cells derived from iPS cells for commercial use. CDI intends its trademarked iCell Cardiomyocytes to be used by pharmaceutical companies to aid in the drug...
7 December 2009 - by Dr Rachael Panizzo 
Researchers at the US Massachusetts Institute of Technology (MIT), lead by Professor Rudolf Jaenisch, have identified genetic pathways that can speed up the process of reprogramming mature adult cells into stem cells, known as induced pluripotent stem cells (iPS cells)....
1 June 2009 - by Dr Rebecca Robey 
Scientists in the US and Korea have announced a new technique for creating embryonic-like stem cells from adult cells. They say that the new method is the first to be completely safe for clinical use and so could bring stem-cell based therapies for a whole host of...
27 April 2009 - by Dr Will Fletcher 
For the first time adult skin cells have been reprogrammed into an embryonic-like state using proteins instead of genes. This feat represents a major step towards overcoming safety concerns associated with many other methods of cell reprogramming. This research was led by members of the Scripps Research...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.